Drug intelligence / Profile preview

Lessina and AG200-15

Development stage: Preclinical
Lead developer: Insud Pharma
Modality: Transdermal Patches → Device-based Delivery → Drug Delivery Systems, Small Molecules
Administration: Oral, Transdermal

Overview

This entry refers to a comparison or study involving two distinct contraceptive products: Lessina and AG200-15. Lessina is a brand-name oral contraceptive containing levonorgestrel and ethinyl estradiol, used for pregnancy prevention. AG200-15 is an investigational transdermal contraceptive patch, developed by Agile Therapeutics, also containing ethinyl estradiol and levonorgestrel, designed for once-weekly application to prevent pregnancy. Studies described as "crossover" designs have compared the pharmacokinetic profiles of AG200-15 with oral contraceptives.

Brand names: Lessina

Targets

PR (Progesterone receptor)ER (Estrogen receptor)

Beyond the preview

Go deeper on Lessina and AG200-15.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Lessina and AG200-15.

Explore the full profile